Type 1 diabetes TrialNet - An international collaborative clinical trials network

Jay S. Skyler, Carla J. Greenbaum, John M. Lachin, Ellen Leschek, Lisa Rafkin-Mervis, Peter Savage, Lisa Spain

Research output: Chapter in Book/Report/Conference proceedingConference contribution

76 Scopus citations


Type 1 Diabetes TrialNet is an international consortium of clinical research centers aimed at the prevention or delay of type 1 diabetes (T1D). The fundamental goal of TrialNet is to counter the T1D disease process by immune modulation and/or enhancement of β cell proliferation and regeneration. To achieve this goal, TrialNet researchers are working to better understand the natural history of the disease, to identify persons at risk, and to clinically evaluate novel therapies that balance potential risks and benefits. The particular focus is on studies of preventive measures. In addition, TrialNet evaluates therapies in individuals with newly diagnosed T1D with preserved β cell function to help determine the risk/benefit profile and gain an initial assessment of potential efficacy in preservation of β cell function, so that promising agents can be studied in prevention trials. In addition, TrialNet evaluates methodologies that enhance the conduct of its clinical trials, which includes tests of outcome assessment methodology, the evaluation of surrogate markers, and mechanistic studies laying the foundation for future clinical trials.

Original languageEnglish (US)
Title of host publicationImmunology of Diabetes V From Bench to Bedside
PublisherBlackwell Publishing Inc.
Number of pages11
ISBN (Print)9781573317337
StatePublished - Dec 2008

Publication series

NameAnnals of the New York Academy of Sciences
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632


  • Clinical trials
  • Immunomodulation
  • Network
  • Prevention
  • Type 1 diabetes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Type 1 diabetes TrialNet - An international collaborative clinical trials network'. Together they form a unique fingerprint.

Cite this